poly ADP-ribose polymerase (PARP) inhibitor

Niraparib - Olaparib - Rucaparib - Talazoparib - Veliparib      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

advanced breast cancer (metastatic)

olaparib
OlympiAD, 2017      NCTolaparibPhysician s choice chemotherapy BRCA-mutated HER-2 negative Risk of bias conclusive-42%-10%

ovarian cancer

niraparib
ENGOT-OV16/NOVA non-gBRCA      NCTniraparibplaceboLow risk of bias suggesting-55%
ENGOT-OV16/NOVA gBRCA, 2017      NCTniraparibplacebo BRCA-mutated Low risk of bias suggesting-73%
olaparib
SOLO2/ENGOT-Ov21      NCTolaparibplacebo BRCA-mutated Low risk of bias suggesting-70%
Ledermann, 2012      NCTolaparidplaceboExploratory suggesting-65%-6%